Page results
-
The TB network for north central London aims to reduce the capital’s high number of new cases and making it easier for patients to receive treatment.
-
The Interventional Oncology Service (IOS) at University College London Hospital (UCLH) is committed to improving the experience and outcomes for patients with cancer through cutting edge image guided interventions.
-
At UCLH we use many different drugs to treat patients with cancer. Chemotherapy is the treatment of cancer with drugs designed to control or destroy the growth of the tumour.
-
This page is intended for women with a cyst or abscess of the Bartholin’s gland. It provides information on the condition and the treatment options available in our hospital.
-
Anaemia is a condition in which the body has fewer red blood cells, or have less haemoglobin in the red blood cells, than normal. Patients who may have anaemia can be referred to general haematology by GPs and hospital doctors.
-
The Central Venous Access Device team provides a nurse-led service to teenagers and adults who have been referred to UCLH for cancer treatment.
-
UCLH is the only Supra-Centre in England to deliver Intracranial Stereotactic Radiosurgery and Stereotactic Radiotherapy Services (SRS/SRT) as part of an integrated neurosurgical and neuro-oncology service to patients.
-
UCLH treats a range of red cell blood disorders and anaemias.
-
This booklet explains what you can expect during recovery from your autologous stem cell transplant.
-
The Headache and Facial Pain Group is internationally recognised as a centre of clinical and academic excellence in the management of complex head and facial pain disorders.
File results
-
FOI/2023/0294 - Patient entertainment
-
FOI/2023/0295 - Strikes and Trust use of the BMA rate card
-
FOI/2023/0296 - Consultant workforce information
-
FOI/2023/0300 - Post-mortem examinations for 2019, 2020, 2021 and 2022
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide